FIG. 1



Sebum
VLDL
Contribution (%)
100
90
80
70
60
50
40
30
20
10
0
4
6
8
10
12
14
Days

FIG. 2



% of Vehicle Control
125
100
75
50
25
0
10-9
10-8
10-7
10-6
10-5
10-4
Concentration (M)

FIG. 3



DMSO
DMSO
0.001 µM
0.003 µM
0.01 µM
0.03 µM
0.1 µM
0.3 µM
1 µM
3 µM
10 µM
Cholesterol Ester
Triglyceride
Free Fatty Acid
Free Cholesterol
Diglyceride
Monoglyceride
Phospholipid

FIG. 4



Relative Change
2.4
2.0
1.6
1.2
0.8
0.4
0.0
Placebo
200mg-BID
Treatments

FIG. 5A



Triacylglycerol : Total
Relative Change
1.75
1.50
1.25
1.00
0.75
0.50
0.25
-3
-2
13
14
Days
Triacylglycerol : Total
Relative Change
1.75
1.50
1.25
1.00
0.75
0.50
0.25
Placebo
200mg-BID
Treatments

FIG. 5B



Free Fatty Acid : Total
Relative Change
2.5
2.0
1.5
1.0
0.5
0.0
-3
-2
13
14
Days
Free Fatty Acid : Total
Relative Change
2.5
2.0
1.5
1.0
0.5
0.0
Placebo
200mg-BID
Treatments

FIG. 5C



Wax Ester : Total
Relative Change
4
3
2
1
0
-3
-2
13
14
Days
Wax Ester : Total
Relative Change
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Placebo
200mg-BID
Treatments

FIG. 6



malonyl-CoA
(% of control)
120
100
80
60
40
20
0
Veh
ACCi
Oral
Veh
ACCi
Topical

FIG.7



Plasma Trigylceride
Ear Skin Lipids
Contribution (%)
100
90
80
70
60
50
40
30
20
10
0
0
2
4
6
8
10
12
14
16
18
20
Days

FIG. 8




Ear Skin
De novo lipogenesis (% of control)
140
120
100
80
60
40
20
0
Veh
ACCi
Veh
ACCi
Oral
Topical
Liver
De novo lipogenesis (% of control)
140
120
100
80
60
40
20
0
Veh
ACCi
Veh
ACCi
Oral
Topical

FIG.9


Hamster Ear Skin Triglyceride
Triglyceride mg/g tissue
100
80
60
40
20
0
Vehicle
ACCi
Treatment